[Federal Register: February 18, 2003 (Volume 68, Number 32)]
[Notices]               
[Page 7792]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18fe03-63]                         


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES


Centers for Disease Control and Prevention


 
Advisory Committee on Immunization Practices: Meeting


    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting.


    Name: Advisory Committee on Immunization Practices (ACIP).
    Times and Dates: 8:30 am-4:30 p.m., February 26, 2003; 8 a.m.-3 
p.m., February 27, 2003.
    Place: Atlanta Marriott Century Center, 2000 Century Boulevard, 
NE., Atlanta, Georgia 30345-3377.
    Status: Open to the public, limited only by the space available.
    Purpose: The Committee is charged with advising the Director, 
CDC, on the appropriate uses of immunizing agents. In addition, 
under 42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children (VFC) program, along with schedules regarding the 
appropriate periodicity, dosage, and contraindications applicable to 
the vaccines.
    Matters to be Discussed: The agenda will include a discussion on 
the influenza vaccine ACIP recommendation; update on U.S. influenza 
vaccine strains; update on vaccine supply; update on smallpox 
program implementation; recommendations for storage of vaccines; 
update on IOM immunization safety review committee meetings; DTaP-
HepB-IPV Vaccine for infants born to HBsAG+ mothers; availability of 
child and adult immunization schedule in PDA format; evidence-based 
tables in ACIP recommendations; public participation in formulating 
vaccine policy; vaccinating cochlear implant recipients for 
meningitis and pneumococcal disease; update on effect of 
pneumococcal conjugate vaccine on disease following introduction; 
impact of varicella vaccination program on herpes zoster; and update 
on the HIV vaccine working group.
    Agenda items are subject to change as priorities dictate.
    As provided under 41 CFR 102-3.150(b), the public health urgency 
of this agency business requires that the meeting be held prior to 
the first available date for publication of this notice in the 
Federal Register.
    Contact Person for More Information: Demetria Gardner, 
Epidemiology and Surveillance Division, National Immunization 
Program, CDC, 1600 Clifton Road, NE., (E-61), Atlanta, Georgia 
30333, telephone 404/639-8096, fax 404/639-8616.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both the CDC and ATSDR.


    Dated: February 10, 2003.
Joseph Salter,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 03-3771 Filed 2-14-03; 8:45 am]

BILLING CODE 4163-18-P